{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:10:36Z","timestamp":1785150636568,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health","award":["R01 AR069874"],"award-info":[{"award-number":["R01 AR069874"]}]},{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health","award":["P50 AR060780"],"award-info":[{"award-number":["P50 AR060780"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome measure have most often been negative. We wanted to assess how the definition of disease onset (first SSc manifestation vs first non-Raynaud manifestation) and varying lengths of disease duration at trial entry as an inclusion criteria functioned. Our objective was to optimize trial inclusion criteria<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We used the prospective, observational University of Pittsburgh Scleroderma Cohort to identify early diffuse SSc patients first evaluated between 1980 and 2015. All had &amp;lt;3\u2009years from first SSc (n\u2009=\u2009481) or first non-Raynaud manifestation (n\u2009=\u2009514) and three or more mRSS scores. We used descriptive, survival and group-based trajectory analyses to compare the different definitions of disease onset and disease duration as inclusion criteria for clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was no appreciable difference between using first SSc manifestation compared with first non-Raynaud manifestation as the definition of disease onset. Compared with other disease durations, &amp;lt;18\u2009months of disease had &amp;gt;70% of patients fitting into trajectories with worsening cutaneous disease over 6\u2009months of follow-up. Longer disease durations demonstrated the majority of patients with trajectories showing an improvement in mRSS (regression to the mean) over 6\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Regardless of whether the first SSc or first non-Raynaud manifestation is used to define disease onset, duration of &amp;lt;18\u2009months at enrolment is preferable. A longer disease duration criterion more frequently results in regression to the mean of the mRSS score, and likely contributes to negative trial outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab075","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:02:56Z","timestamp":1611608576000},"page":"4662-4670","source":"Crossref","is-referenced-by-count":20,"title":["Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-0922","authenticated-orcid":false,"given":"Robyn T","family":"Domsic","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyao","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Laffoon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Steen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lafyatis","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Thomas A","family":"Medsger","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"2021121700313432400_keab075-B1","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/1529-0131(199912)42:12<2660::AID-ANR23>3.0.CO;2-N","article-title":"Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit","volume":"42","author":"Bryan","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B2","first-page":"276","article-title":"A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease","volume":"15","author":"Barnett","year":"1988","journal-title":"J Rheumatol"},{"key":"2021121700313432400_keab075-B3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"2021121700313432400_keab075-B4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/ard.57.11.682","article-title":"Mortality and causes of death in a Swedish series of systemic sclerosis patients","volume":"57","author":"Hesselstrand","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2021121700313432400_keab075-B5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"2021121700313432400_keab075-B6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2397198318823122","article-title":"History of skin thickness assessment and the Rodnan skin thickness scoring method in systemic sclerosis","volume":"4","author":"Medsger","year":"2019","journal-title":"J Scleroderma Relat Disord"},{"key":"2021121700313432400_keab075-B7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/art.1780380309","article-title":"Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions","volume":"38","author":"White","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.7326\/0003-4819-44-1-16","article-title":"Observations on the use of prednisone in patients with progressive systemic sclerosis (diffuse scleroderma)","volume":"44","author":"Rodnan","year":"1956","journal-title":"Ann Intern Maed"},{"key":"2021121700313432400_keab075-B9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","article-title":"Review: Evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0049-0172(75)90017-7","article-title":"Pathogenesis of systemic sclerosis: a vascular hypothesis","volume":"4","author":"Campbell","year":"1975","journal-title":"Semin Arthritis Rheum"},{"key":"2021121700313432400_keab075-B11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0092-8674(03)00422-7","article-title":"Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal","volume":"113","author":"Lauber","year":"2003","journal-title":"Cell"},{"key":"2021121700313432400_keab075-B12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/cdd.2009.124","article-title":"Caspase-3-mediated secretion of connective tissue growth factor by apoptotic endothelial cells promotes fibrosis","volume":"17","author":"Laplante","year":"2010","journal-title":"Cell Death Differ"},{"key":"2021121700313432400_keab075-B13","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1164\/rccm.200308-1111OC","article-title":"T. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis","volume":"169","author":"Ebina","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121700313432400_keab075-B14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/rccm.200308-1151OC","article-title":"Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis","volume":"170","author":"Cosgrove","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121700313432400_keab075-B15","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/art.38381","article-title":"Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis","volume":"66","author":"Domsic","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021121700313432400_keab075-B16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","article-title":"Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database","volume":"74","author":"Maurer","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021121700313432400_keab075-B17","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/978-1-4614-5690-2_479","volume-title":"Encyclopedia of Criminology and Criminal Justice","author":"Sweeten","year":"2014"},{"key":"2021121700313432400_keab075-B18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1089\/neu.2012.2578","article-title":"Group-based trajectory analysis applications for prognostic biomarker model development in severe TBI: a practical example","volume":"30","author":"Niyonkuru","year":"2013","journal-title":"J Neurotrauma"},{"key":"2021121700313432400_keab075-B19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021121700313432400_keab075-B20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2021121700313432400_keab075-B21","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/art.24380","article-title":"Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial","volume":"60","author":"Khanna","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.23501","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease","volume":"58","author":"Postlethwaite","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B23","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B24","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","article-title":"Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center","volume":"63","author":"Pope","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2 Suppl 76","key":"2021121700313432400_keab075-B25","first-page":"151","article-title":"A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis","volume":"31","author":"Takehara","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2021121700313432400_keab075-B26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.22289","article-title":"Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I\/II trial of CAT-192","volume":"56","author":"Denton","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jaad.2005.11.1091","article-title":"A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis","volume":"54","author":"Knobler","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2021121700313432400_keab075-B28","first-page":"71","article-title":"Placebo controlled trial of methotrexate in systemic sclerosis","volume":"14","author":"Das","year":"2005","journal-title":"Mymensingh Med J"},{"key":"2021121700313432400_keab075-B29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B30","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.1780280311","article-title":"Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis","volume":"28","author":"Williams","year":"1985","journal-title":"Arthritis Rheum"},{"key":"2021121700313432400_keab075-B31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2021121700313432400_keab075-B32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021121700313432400_keab075-B33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2017-211912","article-title":"Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study","volume":"77","author":"Herrick","year":"2018","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab075\/36130324\/keab075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4662\/41781671\/keab075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/10\/4662\/41781671\/keab075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:33:19Z","timestamp":1639701199000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/10\/4662\/6121911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":33,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,1,28]]},"published-print":{"date-parts":[[2021,10,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab075","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2021,1,28]]}}}